Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status

Seon-Ah Ha1, Youn Soo Lee2, Seung Min Shin1, Hyun Kee Kim1, Sanghee Kim1, Hong Namkoong1, Hae Joo Kim1, Sang Min Jung1, Yu Sun Lee1, Yeun Jun Chung3, Sang Seol Jung4 and Jin Woo Kim15*

Author Affiliations

1 Department of Molecular Genetic Laboratory, College of Medicine, The Catholic University of Korea, Seoul 137-040, Korea

2 Department of Hospital pathology, College of Medicine, The Catholic University of Korea, Seoul 137-040, Korea

3 Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 137-040, Korea

4 Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul 137-040, Korea

5 Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul 137-040, Korea

For all author emails, please log on.

BMC Cancer 2009, 9:51  doi:10.1186/1471-2407-9-51

Published: 11 February 2009

Abstract

Background

Oncoprotein HCCR-1 functions as a negative regulator of the p53 and contributes breast tumorigenesis. The serum HCCR-1 assay is useful in diagnosing breast cancer and mice transgenic for HCCR developed breast cancers. But it is unknown how HCCR-1 contributes to human breast tumorigenesis.

Methods

Oncogene HCCR-1 expression levels were determined in normal breast tissues, breast cancer tissues and cancer cell lines. We examined whether HCCR-1 protein expression in breast cancer is related to different biological characteristics, including ER, PR, p53 genotype, and HER2 status in 104 primary breast cancer tissues using immunohistochemical analyses.

Results

HCCR-1 was upregulated in breast cancer cells and tissues compared with normal breast tissues. In this study, overexpression of HCCR-1 was well correlated with known breast cancer prognostic markers including the presence of steroid receptors (ER and PR), p53 mutation and high HER2 overexpression. HCCR-1 was not detected in the ER-negative, PR-negative, p53 negative and low HER2 breast cancer tissues. These data indicate that the level of HCCR-1 in breast cancer tissues is relatively well correlated with known breast cancer factors, including the HER2 overexpression, p53 mutation, and ER/PR status.

Conclusion

Determination of HCCR-1 levels as options for HER2 testing is promising although it needs further evaluation.